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permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.SUMMARYThe fetal liver kinase 1 (FLK-1)+ hemangioblast can generate hematopoietic, endothelial, and smooth muscle cells (SMCs). ER71/ETV2,
GATA2, and SCL form a core transcriptional network in hemangioblast development. Transient coexpression of these three factors during
mesoderm formation stage in mouse embryonic stem cells (ESCs) robustly enhanced hemangioblast generation by activating bone
morphogenetic protein (BMP) and FLK-1 signaling while inhibiting phosphatidylinositol 3-kinase, WNT signaling, and cardiac output.
Moreover, etsrp, gata2, and scl inhibition converted hematopoietic field of the zebrafish anterior lateral platemesoderm to cardiac. FLK-1+
hemangioblasts generated by transient coexpression of the three factors (ER71-GATA2-SCL [EGS]-induced FLK-1+) effectively produced
hematopoietic, endothelial, and SMCs in culture and in vivo. Importantly, EGS-induced FLK-1+ hemangioblasts, when codelivered with
mesenchymal stem cells as spheroids, were protected from apoptosis and generated functional endothelial cells and SMCs in ischemic
mouse hindlimbs, resulting in improved blood perfusion and limb salvage. ESC-derived, EGS-induced FLK-1+ hemangioblasts could pro-
vide an attractive cell source for future hematopoietic and vascular repair and regeneration.INTRODUCTION
Pluripotent stem cells provide an exciting opportunity in
the field of basic as well as regenerative biology because
of their unique capacity to differentiate in culture into all
somatic cells that form an individual. Current efforts are
aimed at generating a preferred somatic cell type bymanip-
ulating growth factors added to culture media. While these
efforts have advanced the field, derivation of a homoge-
nous specific cell population from embryonic stem cells
(ESCs) or induced pluripotent stem cells (iPSCs) still re-
mains as a major challenge in the field. Successful deriva-
tion of a desired somatic cell lineage from ESCs or iPSCs
would likely to be advanced by comprehensive under-
standing of how specification of that particular cell lineage
is accomplished in the developing embryo. As for blood
and vessel development, tracking a receptor tyrosine kinase
fetal liver kinase 1 (FLK-1) expression has been instru-
mental. Specifically, cell lineage tracing studies have
demonstrated that FLK-1+ mesoderm contributes to primi-
tive and definitive blood, endothelial cells, and cardiac and
skeletal muscles (Lugus et al., 2009; Motoike et al., 2003).166 Stem Cell Reports j Vol. 1 j 166–182 j August 6, 2013 j ª2013 The AuthFLK-1+ (or KDR+ in human) mesoderm isolated from ESCs
or embryos can generate hematopoietic, endothelial, and
smooth muscle cells as well as cardiac cells (Choi et al.,
1998; Faloon et al., 2000; Yamashita et al., 2000; Ema
et al., 2003; Huber et al., 2004; Kennedy et al., 2007; Katt-
man et al., 2006; Moretti et al., 2006; Yang et al., 2008).
Importantly, hemangiogenic or cardiogenic potential of
the FLK-1+ mesoderm can be segregated by the platelet-
derived growth factor receptor a (PDGFRa) expression in
both mouse and human, such that, while the FLK-
1+PDGFRa cell population is enriched for the heman-
giogenic potential, FLK-1+PDGFRa+ cell population is
enriched for the cardiogenic potential (Kattman et al.,
2011; Liu et al., 2012).
Molecularly, there is an antagonistic relationshipbetween
the hemangiogenic and cardiogenic mesodermal outcome.
For example, enforced Er71 expression leads to an increase
in hematopoietic and endothelial cell output but a decrease
in cardiac output. Conversely, Er71 deficiency results in
defective hematopoietic and endothelial cell output but
enhanced cardiac outcome (Lee et al., 2008; Liu et al.,
2012). Similarly, the hematopoietic program is inhibitedors
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Enhanced Hemangioblast Generation from ESCsby enforced Mesp1 or Nkx2-5 expression, which promotes
cardiac differentiation (Caprioli et al., 2011; Lindsley et al.,
2008).
Herein, we reasoned that hemangioblast generation from
ESCs could be enhanced by inhibiting cardiac output with
defined hemangiogenic factors. We presumed that the
candidate factors should be preferentially expressed within
the hemangioblast population, that they could individually
skew toward the hemangiogenic output, and that the skew-
ingeffect couldbemostdramaticwhen thecandidate factors
were coexpressed.We identify ER71,GATA2, andSCLas core
factors in hemangioblast development. Transient coexpres-
sionof these three factors duringmesoderm formation stage
robustly enhancedFLK-1+hemangioblast (FLK-1+PDGFRa)
production while concomitantly inhibiting cardiac out-
come from differentiating ESCs. Such FLK-1+ hemangio-
blasts generated functional endothelial and smooth muscle
cells in culture as well as in ischemic mouse hindlimbs,
resulting in improved blood perfusion and limb salvage.RESULTS
FLK-1+PDGFRa Cells from ESCs Can Be Potently
Generated by Temporal ER71, GATA2, and SCL
Coexpression
We previously reported gene expression profiling of the
presumptive hemangioblasts, FLK-1+SCL+ (Chung et al.,
2002; Lugus et al., 2007). Focusing on the genes that were
preferentially expressed within FLK-1+SCL+ cells or FLK-1+
cells (Figure S1A available online), we determined if any
of these could skew mesoderm toward the hemangiogenic
FLK-1+PDGFRa outcome from ESCs. To this end, we
generated A2 ESCs expressing single candidate genes in a
doxycycline (DOX)-inducible manner (Ismailoglu et al.,
2008). We induced candidate genes from day 2 and
analyzed FLK-1 and PDGFRa expression between days 3
and 4, mesoderm formation, and patterning stage. While
the majority of the candidate genes did not show skewing
potential, we could detect skewing outcome toward FLK-
1+PDGFRa mesoderm with Er71-, Gata2-, or Scl-enforced
expression (Figures 1A, S2A, and S2B). Parent A2 or other
ESC line R1 showed similar differentiation potential gener-
ating FLK-1+ and/or PDGFRa+ cells (Figure S1B), indicating
that genetic manipulation did not alter the differentiation
potential of the A2 ESCs.
Of the three factors, enforced Er71 expression readily
generated FLK-1+PDGFRa cells as early as day 3. However,
the FLK-1+ PDGFRa skewing effect was not effectively
maintained at later time points, as we could detect PDGFRa
expression on day 4 (Figure 1A). Enforced Scl expression
resulted in slightly different kinetics, such that FLK-
1+PDGFRa cells were most abundant at a later time point,Stem Cday 4. Enforced Gata2 expression appeared to mainly
suppress FLK-1+PDGFRa+ cells without significant increase
in FLK-1+PDGFRa cells. As the analyses of the enforced
Er71, Gata2, or Scl expression suggested that these three
factors might function synergistically, we next determined
if temporal coexpression of these three factors were even
more powerful in the skewing effect. Thus, we generated
A2 ES cells coexpressing Er71, Gata2, and Scl in a DOX-
inducible manner. Notably, only the FLK-1+PDGFRa cells,
not FLK-1+PDGFRa+ nor PDGFRa+, in both serum (Fig-
ure 1A) and serum-free conditions (Figure 4E) were
generated when we coexpressed the three factors. FLK-
1+PDGFRa+ cells were still suppressed at day 4. Hematopoi-
etic and endothelial cell transcription factor and surface
receptor genes were strongly upregulated in these FLK-
1+PDGFRa cells (Figure 1B). On the other hand, cardiac
transcription factors, including Mesp1 and Islet1 as well
as Pdgfra genes, were greatly suppressed in these FLK-
1+PDGFRa cells. Collectively, temporal coexpression of
Gata2 and Scl together with Er71 results in themost power-
ful effect generating FLK-1+PDGFRa cells.
ER71, GATA2, and Scl-Induced Hemangioblast Can
Further Differentiate into Hematopoietic and
Endothelial Cells In Vitro and In Vivo
Todetermine if FLK-1+PDGFRa cells generated by the tran-
sient Er71,Gata2, and Scl coexpression, designated as ER71-
GATA2-SCL (EGS)-induced FLK-1+,were enriched for ‘‘bona
fide’’ hemangioblasts, we subjected day 3 embryoid body
(EB) cells, control and DOX-treated, to blast colony assay,
an in vitro measure of hemangioblast (Choi et al., 1998).
Remarkably, DOX-treated EB cells, compared to controls,
generated greatly enhanced number of blast colonies (Fig-
ure 1C). More importantly, blast colonies were readily
generated with DOX from serum-free conditions plus
bone morphogenetic protein 4 (BMP-4), which normally
do not support blast colony formation (Figures 1D and
1E). To determine if indeed all blast colonies developed
from FLK-1+ cells, we sorted FLK-1+ cells from day 3 EBs,
control and DOX-treated, and subjected to blast colony
assay. Again, FLK-1+PDGFRa cells generated from DOX-
treated EBs produced an increased blast colony number
compared to control FLK-1+ cells (Figure 1F). Blast cells are
capable of generating blood, endothelial, and smoothmus-
cle cells (Choi et al., 1998; Ema et al., 2003; Yamashita et al.,
2000). To further validate that the differentiation potential
of blast colonies generated from EGS-induced FLK-1+ cells
were the same as the controls, we subjected individual blast
colonies to further differentiation into hematopoietic,
endothelial, and smooth muscle cells. Similar percentage
of blast colonies from control and DOX-treated EBs gener-
ated both hematopoietic and adherent cells (Figure S1C).
Adherent cells contained both CD31+ (or VE-CADHERIN+)ell Reports j Vol. 1 j 166–182 j August 6, 2013 j ª2013 The Authors 167
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Enhanced Hemangioblast Generation from ESCsand SMA-a+ cells, indicating that DOX treatment resulted
in enhanced hemangioblast generation without altering
their differentiation potential (Figures 1G, 1H, and S1D).
As expected, FLK-1+ cells, control and DOX-treated,
robustly generated hematopoietic (CD45+ and CD41+)
and endothelial (VE-CADHERIN+ and CD31+) cells when
cultured on OP9 cells (Figure 1J and S1E). Gene expression
analyses also corroborated with cell surface marker studies
(Figure 1K). Lymphatic endothelial cell marker genes,
including Prox1, Vegfr3, and Lyve1, were also highly ex-
pressed in EGS-induced FLK-1+ and differentiated progeny
cells (Figures 1B, 1J, and 1K).
Functional hematopoietic and endothelial cell outcome
from EGS-induced FLK-1+ cells was further determined
in vivo by Matrigel plug assay. Control FLK-1+ or EGS-
induced, FLK-1+-derived GFP+CD31+ as well as GFP+SMA-
a+ cells were detected (Figures 1L, S1F, and S1G). The
occurrence of GFP+CD45+ cells was more frequent from
Matrigel plugs obtained from EGS-induced FLK-1+ cells
(Figures 1L, S1G, and S1H). In some cases, such vessels
were filled with round GFP+ but DAPI negative cells, sug-
gesting these cells could be mature erythrocytes derived
from FLK-1+ hemangioblasts (Figure S1G). Collectively,
FLK-1+ cells, control or EGS-induced, contain functional
progenitors for hematopoietic, endothelial, and smooth
muscle cells. EGS-induced FLK-1+ cells are highly effective
in generating blood, endothelial cells, and smooth muscle
cells in vivo.Figure 1. Enhanced FLK-1+PDGFRa Hemangioblast Generation b
(A) iEr71, iGata2, iScl, or iEGS (= iEr71-2A-Gata2-2A-Scl) EBs were tre
indicated times. Numbers indicate the percentage of live cells gated w
experiments are shown.
(B) FLK-1+ cells were sorted from day 3 iEGS EBs (±DOX from day 2) and
shown as mean ± SD of three independent experiments.
(C and F) Day 3 iEGS EBs (±DOX from day 2) were subjected to blas
independent experiments **p < 0.01, compared to DOX.
(D) iEGS ESCs were differentiated in serum-free conditions with BMP-4
replated on day 3, 3.25, or 3.5. Blast colonies and secondary EBs were
independent experiments, **p < 0.01, compared to DOX.
(E) iEGS ESCs were differentiated as in (D) and analyzed for FLK-1 an
(F) FLK-1+ cells sorted from day 3 iEGS EBs (±DOX from day 2) were subj
of four independent experiments **p < 0.01, compared to DOX.
(G and H) Individual blast colonies were picked and cultured on typ
Bright-field images of hematopoietic and adherent cells are shown (G
cells were immunostained for CD31 (red), VE-CADHERIN (red), SMAa (
CD31 and VE-CADHERIN; 50 mm for SMAa.
(I–K) FLK-1+ cells were sorted from day 3 iEGS EBs (±DOX from day 2
sorting-analyzed for CD41, CD45, CD31, LYVE-1, and VE-CADHERIN (J) o
as mean ± SD of three independent experiments.
(L) FLK-1+ cells were sorted as in (I), infected with GFP retrovirus, mix
nonobese diabetic/severe combined immunodeficiency/interleukin
assessed for GFP+CD31+ or GFP+SMAa+ by immunostaining. Nuclei ar
See also Figures S1 and S2 and Table S2.
Stem Cetsrp, gata2, and scl Inhibition Can Successfully
Convert the Hematopoietic Field of the Zebrafish
Anterior Lateral Plate Mesoderm to a Cardiac Field
To further ascertain that cardiogenic versus hemangiogenic
outcome can be manipulated by the three hemangiogenic
transcription factors, we determined if the cardiac field can
be extended by suppressing er71, gata2, and scl expression
in zebrafish. Fate-mapping studies in zebrafish have estab-
lished that, while blood and endothelial cells originate
from the rostral part of the anterior lateral plate mesoderm
(ALPM), cardiac cell lineages originate from themedial and
lateral parts (Figures 2A and 2B; Schoenebeck et al., 2007).
Moreover, limiting blood and vessel specification resulted
in expansion of cardiac progenitors (Schoenebeck et al.,
2007). We observed that etsrp morpholino (MO) injection
alone was sufficient to convert the hemangiogenic field
to cardiac, as evidenced by hand2 expression in the rostral
part (Figure 2C), with concomitant loss of fli1a expression,
a gene critical for the hemangioblast specification in zebra-
fish (Liu et al., 2008). This effect was specific to the ALPM,
as the lateral fli1 expression was not affected (Figure 2K).
More importantly, etsrp-deficient embryos readily ex-
pressed hand2 in the rostral region of the ALPM (Figure 2D).
scl MO injection also resulted in a similar extension of the
cardiac field (Figure 2E). Although gata2MOdid not extend
hand2 expression rostrally, the hand2 expression domain
was expanded within the medial/lateral part (Figure 2F).
Whereas 75% of wild-type embryos coinjected withy Temporal Er71, Gata2, and Scl Coexpression
ated with DOX from day 2 and analyzed for FLK-1 and PDGFRa at
ithin each quadrant. Representative results from four independent
analyzed for gene expression. Expression levels relative to Gapdh are
t colony assay. Colony numbers are shown as mean ± SD of four
(10 ng/ml) and DOX added from day 0 and day 2, respectively, and
counted on day 4. Colony numbers are shown as mean ± SD of four
d PDGFRa on day 3.5.
ected to blast colony assay. Colony numbers are shown as mean ± SD
e IV collagen-coated microtiter well in the presence of cytokines.
), scale bar: 50 mm. After removing hematopoietic cells, adherent
green), and DAPI nuclear staining (blue) (H). Scale bar: 20 mm for
), cultured on OP9 cells for 6 days, and fluorescence-activated cell
r gene expression (K). Expression levels relative to Gapdh are shown
ed in with OP9 cells and Matrigel, and injected subcutaneously into
2 Rg/ mice. After 2 weeks, Matrigel plugs were excised and
e shown in blue with DAPI (scale bar: 50 mm).
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Enhanced Hemangioblast Generation from ESCsgata2 and sclMOs displayed the rostral extension of hand2
expression, 100% of the etsrp heterozygous (etsrpy1 1/+) em-
bryos (Pham et al., 2007), coinjected with these two MOs
showed anterior enlargement of hand2 expression (Figures
2G and 2J). Importantly, while 80% of embryos coin-
jected with etsrp and sclMO resulted in rostral hand2 exten-
sion, 100% of the embryos showed conversion of the
hemangiogenic field to cardiac when coinjected with all
three MOs (Figures 2H and 2I). These results suggest the
cooperativity among Er71, Scl, and Gata2 in promoting
hemangiogenic mesoderm development. Collectively,
simultaneous modulation of Er71, Gata2, and Scl expres-
sion in ESC or zebrafish has profound effect on the heman-
giogenic outcome.
ER71, GATA2, and SCL-Mediated Genetic Program in
Hemangioblast Development
The earlier and robust effect of Er71, compared to Gata2 or
Scl, on the FLK-1+ PDGFRa, skewing both in ESC and
zebrafish models, suggested that ER71 functions upstream
of GATA2 and SCL. Indeed, we previously reported that
Er71 expression in embryos and EBs is transient (Lee
et al., 2008). The onset of Er71 expression in wild-type
EBs precedes that of Gata2 and Scl expression (Figure S3A).
Moreover,Gata2or Scl expression inEBswasnot detected in
the absence of ER71 (Figure S3A). We also detected ER71
occupancy on the Scl promoter region (Figure S4). More-
over, Er71-enforced expression resulted in robust Gata2
and Scl upregulation. On the other hand, Gata2 or Scl-
enforced expression failed to upregulate Er71 expression
(Figure S3B). We conclude that ER71 establishes Gata2
and Scl expression during hemangioblast development.
To better understand genetic program-regulating heman-
gioblast formation, we compared global temporal gene
expression changes by enforced ER71, GATA2, and Scl
coexpression. Specifically, we saw an upregulation of
Er71, Gata2, and Scl expression by 6 hr after DOX addition,
indicating that 6 hr DOX treatment was sufficient to
induce these exogenous genes. Thus, RNA from day 2.25
(6 hr after DOX addition), day 2.5 (12 hr after DOX addi-
tion), and day 3 (24 hr after DOX addition) EB cells was sub-
jected to microarray analyses. Notably, Fli-1, Lmo2, Esam,
Sox7, Sox18, Hey1, Flk-1, and Cdh5 expression was signifi-Figure 2. Combinatorial Suppression of er71/etsrp, gata2, and scl
Mesoderm
(A–I) In situ hybridization depicts hand2 and fli1a expression in un
(E; 12.5 ng), gata2 MO (F; 33.4 ng), gata2 (33.4 ng)+scl (12.5 ng) MO
(33.4 ng) MOs (I)-injected embryos, and etsrp/ embryos (D).
(J) Expression of hand2 in gata2 (33.4 ng)+scl (12.5 ng) MOs-inject
phenotype. (A–J) Seven-somite stage, dorsal views, anterior to the l
(K) Lateral view of flia expression in uninjected, etsrp MO, or etsrp+s
See also Table S4.
Stem Ccantly upregulated within 6 hr after DOX addition, sug-
gesting that these genes are presumably direct targets of
ER71, GATA2, and Scl (Figures 3A and 3B). Indeed, we pre-
viously demonstrated that Flk-1 and Ve-cadherin/Cdh5 are
ER71 direct targets (Lee et al., 2008; Liu et al., 2012). Recent
studies have reported that Lmo2 is also an ER71 direct target
(Koyano-Nakagawa et al., 2012). While hematopoietic and
endothelial cell genes became progressively upregulated
over the course of 24 hr DOX treatment, cardiac genes,
including Hand1, Isl1, and Mesp1, were progressively
downregulated within the same time frame (Figures 3A
and 3B). At the same time, Flk-1 expression and down-
stream signaling pathway genes were greatly upregulated
by 24 hr after DOX addition (Figures 3C–3E). Cell adhesion
molecules as well as Bmp-4 and Bmp-6 were also upregu-
lated. On the other hand, BMP-4 inhibitors, including
Follistatin and Cer-1 gene expression, were greatly in-
hibited. WNT signaling and epithelial-mesenchymal
transition (EMT) pathway genes were also significantly
downregulated (Figures 3C–3E; Table S1). Collectively,
our data suggested that enforced Er71, Gata2, and Scl coex-
pression resulted in activation of BMP and FLK-1 signaling
and inhibition of EMT and WNT signaling.
We further performed biochemical analyses to confirm
the signaling pathways identified by the global gene
expression profiling. DOX treatment resulted in an in-
crease of the total SMAD1/SMAD5/SMAD8 protein levels
as well as a significant enhancement of phospho-SMAD1/
SMAD5/SMAD8, indicating that BMP signaling was indeed
activated (Figure 4A). AKT/protein kinase B (AKT) phos-
phorylation was greatly reduced, but ERK phosphorylation
was strongly enhanced by DOX treatment (Figure 4A). As
total AKT or ERK protein levels remained the same, ER71,
GATA2, and SCL induce hemangioblasts by selectively
activating the map kinase pathway. Phopho-glycogen syn-
thase kinase 3b (GSK3b) levels at serine 9 were greatly
decreased upon DOX treatment (Figure 4A). The total
amount of GSK3b remained the same. DOX treatment
also resulted in lymphoid enhancer-binding factor-1
(LEF1) inhibition (Figure 4A), a key component in WNT
target gene expression. Potentially, ER71-, GATA2-, and
SCL-mediated WNT inhibition is achieved both by GSK-
3b-bCATENIN as well as LEF1 inhibition. As for EMT,Promotes Cardiogenic Output in Zebrafish Anterior Lateral Plate
injected (A), control (B), and etsrp MO embryos (C; 3 ng), scl MO
s (G), etsrp (3 ng)+scl (3 ng) MOs (H), etsrp (3 ng)+scl (3 ng)+gata2
ed etsrp+/+ and etsrp+/ embryos. The numbers show the severe
eft.
cl+gata2 MO-injected embryos. Scale bar: 500 mm.
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Enhanced Hemangioblast Generation from ESCsDOX treatment (from day 2 or 3) greatly suppressed
N-CADHERIN expression (Figure 4B). At the same time,
genes involved in EMT processes, including Snail1 and
Twist1, were also suppressed by DOX addition (Figure 4C).
CHIR99021, a GSK3b inhibitor, could partially rescue
Snail1 inhibition by DOX treatment (Figure 4D) but not
Mesp1 suppression or FLK-1+PDGFRa+ cardiac mesoderm
(not shown). Notably, activation of the map kinase
pathway and inhibition of the phosphatidylinositol
3-kinase (PI3K)/AKT pathway was readily observed by en-
forced Er71 expression alone. SMAD1/SMAD5 activation
and WNT inhibition was readily observed by enforced
Gata2 and Scl expression, respectively (Figure 4A). This
suggested that ER71, GATA2, and SCL may distinctly
contribute to hemangioblast development, and the com-
bined sum of ER71, GATA2, and SCL activity is required
for the most efficient hemangioblast generation.
Since the PI3K pathway appeared to negatively regulate
hemangioblast formation, we tested if we could produce
FLK-1+PDGFRa cells even more robustly by adding PI3K
inhibitor. The percentage of FLK-1+PDGFRa cells gener-
ated was significantly higher when we added DOX and
PI3K inhibitor together (Figure 4E). On the other hand,
FLK-1+PDGFRa cells were generated less when a map
kinase inhibitor was added together with DOX, indicating
that the map kinase pathway positively regulates the FLK-
1+PDGFRa cell formation (Figure 4E).
EGS-Induced FLK-1+ Cells Can Potently Enhance
Angiogenic Repair and Regeneration
We tested if ESC-derived, EGS-induced FLK-1+ (= FLK-
1+(+DOX)) cells could be used for angiogenic repair
and regeneration. Remarkably, mesenchymal stem cells
(MSCs) delivered as spheroids were superior to single
MSC cells in supporting vascular therapeutic activity in a
mousemodel of hindlimb ischemia, as they were protected
from apoptosis and secreted higher levels of angiogenicFigure 3. ER71, GATA2, and SCL-Mediated Genetic Program Regul
(A) Gene expression was assessed by microarray analysis at the indica
gene from three independent experiments is shown as heat map. Inten
of the DOX samples. Red shading indicates increased expression, an
(B) Kinetic expression levels of the indicated cell lineage markers ov
without (dashed line) DOX is shown by qRT-PCR analysis. Data are pres
(C) Heat map presents the relative expression of a subset of genes a
pathways. Intensity values used in the heat maps are in log2 and norm
three independent experiments are shown.
(D and E) Networks of the pathway regulation were created using M
samples is shown. Data are presented as the mean values ± SD from th
focused on significantly affected interactions. Signaling pathways invo
Overlapping circles contain differentially expressed genes common to
blue solid circles indicate downregulated genes. Green arrows show a
See also Figures S3 and S4 and Tables S1 and S2.
Stem Cfactors (Bhang et al., 2012; Shim et al., 2012). Thus, we
determined if MSCs could be used as vehicles for delivering
EGS-induced FLK-1+ cells. To this end, we used human
MSCs (hMSCs; from female) to distinguish the contribu-
tion of EGS-induced FLK-1+ cells and MSCs in angiogenic
repair. We first evaluated if EGS-induced FLK-1+ cells could
be protected from apoptosis while preserving endothelial
differentiation potential by coculturing with hMSCs as
spheroids. Specifically, spheroids generated between EGS-
induced FLK-1+ and hMSCs in different ratios (1:1, 1:5,
and 1:10) were analyzed for the best condition that gave
maximal cell survival of EGS-induced FLK-1+ cells after
switching to hypoxia (1% oxygen) to mimic an in vivo
ischemic environment. EGS-induced FLK-1+ cells under
hypoxia readily became apoptotic when cocultured with
hMSCs as single cells (Figures 5A and 5B). Spheroids
containing only EGS-induced FLK-1+ cells also displayed
multiple apoptotic cells (Figures 5A and 5B). However,
EGS-induced FLK-1+ cells displayed significantly enhanced
survival when coculturedwith hMSCs as spheroids (Figures
5A and 5B). Consistently, while Bcl-2 expression was
readily detectable in (FLK-1+(+DOX)+hMSC) spheroids,
p53 expression levels were high in single-cell culture or
spheroids containing only FLK-1+(+DOX) cells (Figures
5C, S5A, and S5B). Of the conditions, the 1:5 group
showed the maximal cell viability. Mitochondrial meta-
bolic activity was also significantly higher in the (FLK-
1+(+DOX)+hMSC) spheroids (1:5 ratio) compared to others
(Figure S5C).
Previous studies have demonstrated that hMSCs readily
upregulated hypoxia-inducible factor 1a (HIF-1a) in spher-
oids in hypoxia (Bhang et al., 2012; Shim et al., 2012).
Consistently, HIF-1a expression was readily detected in
(FLK-1+(+DOX)+hMSC) spheroids, with the expression
level being the highest in spheroids containing EGS-
induced FLK-1+ cells and hMSCs in a 1:5 ratio (Figures
5C, S5D, and S5E). HIF-1a upregulation resulted inating Hemangioblast Development
ted times (hr) after DOX addition. The average intensity for a given
sity values used in the heat maps are in log2 and normalized to mean
d blue shading indicates decreased expression.
er the time course of iEGS ESCs differentiation with (filled line) or
ented as the mean values ± SD from four independent experiments.
t the 12 and 24 hr after DOX addition implicated in the indicated
alized to mean of the DOX samples at each time point. Data from
etaCore. (D) Fold-change of pathway genes in +DOX versus DOX
ree independent experiments. (E) Representative pathways that are
lved in BMP-4 is in blue; VEGF, green; WNT, brown; and EMT, yellow.
both pathways. Red solid circles indicate upregulated genes, and
ctivation, and red arrows show suppression.
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Figure 4. ER71, GATA2, and Scl-Mediated
Signaling Pathways in Hemangioblast
Development
(A) iEr71, iGata2, iScl, or iEGS ESCs were
differentiated in serum-free conditions with
DOX added from day 2. Day 4 EB-lysates were
analyzed for signaling molecules by immu-
noblotting.
(B) iEGS EB cells were plated onto collagen
I-coated slides on day 2 and stained with
antibodies against E-CADHERIN (green) or
N-CADHERIN (red) on day 4. N-CADHERIN
protein expression levels in day 4 iEGS EBs
(±DOX) are also shown by immunoblot
analysis.
(C) Mouse EMT signaling SA-Bioscience QRT-
PCR array on iEGS day 4 EBs (±DOX from day 2)
are shown as scattered plots of fold changes
normalized to three housekeeping genes
for +DOX versus DOX. Red dots are down-
regulated genes in +DOX.
(D) iEGS ESCs were differentiated, CHIR99021
and DOX added from days 2–4, and analyzed
for Snail1 and Mesp1 expression. Expression
levels relative to Gapdh are shown as mean ±
SD of three independent experiments. (The
asterisk shows p < 0.01 compared to +DOX
group).
(E) iEGS ESCs were differentiated in serum-
free conditions, inhibitors and DOX added
from day 2, and analyzed for FLK-1 and
PDGFRa expression on day 4. PI3K inhibitors
include LY294002 (10 mM) and Wortmannin
(200 nM), MEK1/2 inhibitors include U0126
(10 mM) and PD184161 (10 mM).
See also Table S2.
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Enhanced Hemangioblast Generation from ESCsenhanced human vascular endothelial growth factor
(VEGF), basic fibroblast growth factor (bFGF), hepatocyte
growth factor (HGF) gene expression, and protein produc-
tion asmeasured by secreted protein levels. Angiogenic fac-
tor production was most robust in spheroids containing
EGS-induced FLK-1+ cells and hMSCs in a 1:5 ratio (Figures
5D, 5E, and S5F). Consequently, endothelial cells were effi-
ciently generated in spheroids containing EGS-induced
FLK-1+ cells and hMSCs in a 1:5 ratio (Figures 5F and 5G).
Spheroids containing only hMSCs did not express any
endothelial cell genes (not shown). HIF-1a, mouse VEGF,
or FGF expression was modest in spheroids generated
with only EGS-induced FLK-1+ cells (Figure 5C; data not174 Stem Cell Reports j Vol. 1 j 166–182 j August 6, 2013 j ª2013 The Authshown). Vitronectin and laminin gene expression was effi-
ciently induced in all spheroids, indicating that three-
dimensional culture conditions augmented extracellular
matrix protein production and cell-cell interactions (Fig-
ures 5H, S5G, and S5H). We conclude that ESC-derived,
EGS-induced FLK-1+ cells can be protected from hypoxia-
induced apoptosis and further differentiate into endothe-
lial cells when cocultured with MSCs as spheroids.
We assessed therapeutic efficacy of the (FLK-
1+(+DOX)+hMSC) spheroids in a mouse model of hind-
limb ischemia. Specifically, we induced hind-limb ischemia
in female nude mice, intramuscularly injected spheroids
containing EGS-induced FLK-1+ cells and hMSCs in a 1:5ors
Figure 5. hMSCs Promote EGS-Induced FLK-1+ Cell Viability and Endothelial Cell Differentiation when Cocultured as Spheroids
Cells were cultured under hypoxic condition (1% oxygen).
(A and B) Cell viability was determined by fluorescein diacetate-ethidium bromide staining (A) (green: live cells; red: dead cells) or by
neutral red assay (B) (*p < 0.01 compared to the FLK-1+(+DOX) spheroid group; three independent experiments).
(C) RT-PCR analysis of Bcl-2, p53, hypoxia-inducible factor-1a, and angiogenic factors. Representative results from three independent
experiments are shown.
(D and E) Angiogenic factors released from single cells and spheroids were determined by ELISA (*p < 0.01 compared to the FLK-1+(+DOX)
spheroid group; three independent experiments).
(F and G) Quantification of Cd31 and Cdh5 expression was determined by qRT-PCR. Expression levels relative to Gapdh are shown as mean ±
SD of three independent experiments. The asterisk indicates p < 0.01 compared to the FLK-1+(+DOX) spheroid group.
(H) Immunoblot analysis of extracellular matrices (LAMININ and VITRONECTIN).
See also Figure S5 and Table S2.
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Enhanced Hemangioblast Generation from ESCsratio (33 106 cells/limb, 53 105 EGS-induced FLK-1+ cells +
2.5 3 106 hMSCs), and assessed the EGS-induced FLK-1+
cell contribution to the recovery of the hind-limb
ischemia by the presence of Y chromosome-positive cells
(parent ESCs are male, XY). Three days after ischemia
induction, the (FLK-1+(+DOX)+hMSC) spheroid-recipient
group contained significantly less caspase-3 and Y-positive
cells (apoptotic cells, arrows) in the ischemic limb
compared to the FLK-1+(+DOX) spheroid-recipient group
(Figures 6A–6C). Y-positive cells were more abundant
in the (FLK-1+(+DOX)+hMSC) spheroid-recipient group
compared to the FLK-1+(+DOX) spheroid-recipient group
(Figure 6D). (FLK-1+(+DOX)+hMSC) spheroid transplan-
tation group displayed enhanced antiapoptotic gene
expression (Bcl-2) and reduced proapoptotic factor
(p53) gene expression (Figures 6E and 6F). Inflammation
and muscle degeneration was attenuated in the (FLK-
1+(+DOX)+hMSC) spheroid-recipient group compared to
that of FLK-1+(+DOX) spheroid-recipient group, as judged
by hematoxylin and eosin (H&E) staining (Figure 6G).
Additionally, significant amount of human VEGF and
FGF2 were detected in mouse ischemic tissues in the
(FLK-1+(+DOX)+hMSC) spheroid-recipient group com-
pared to the FLK-1+(+DOX) spheroid transplantation group
(Figures 6E and 6H).
Twenty-eight days after ischemia induction, mice that
received no treatment showed extensive muscle degenera-
tion and inflammation in the ischemic region (Figures 6I
and 6J), resulting in a complete limb loss (95.5%; n = 22)
or severe limb necrosis (4.5%; Figure 6K). Mice that
received FLK-1+(+DOX) spheroids displayed similar muscle
degeneration and limb loss (n = 5; data not shown). Mice
that received hMSC spheroids did significantly better
with decreased limb necrosis (Figure 6K). However, these
mice still showed muscle degeneration and inflammation
in the ischemic region (Figures 6I and 6J) and 27.3% of
them ultimately lost limb (Figure 6K). Similar to miceFigure 6. Enhanced Ischemic Limb Salvage and Vascular Repair b
(A) CASPASE-3 and Y-chromosome staining from day 3 samples. Apopt
Y-chromosome (green), cell nuclei: DAPI (blue), respectively (scale b
induced FLK-1+ cells.
(B–D) The ratio of CASPASE-3 and Y-chromosome positive cells in the
(E) Immunoblot analysis of anti- and proapoptotic factor and angiog
(F) Quantification of Bcl-2 and p53 determined by qRT-PCR (*p < 0.0
(G) H&E staining of histological ischemic limb sections 3 days after
(H) Amount of angiogenic factors produced in ischemic lesion as det
spheroid group; 24 mice/group).
(I and J) H&E staining (I) and Masson’s trichrome staining (J) of h
indicates fibrosis in [J], scale bar = 200 mm). The asterisk indicates p
(K and L) Representative photographs of physiological status (K) and
0, 7, 14, 21, and 28 days after treatments. All photographs were taken a
group.
See also Figures S6 and S7 and Table S2.
Stem Cthat received hMSC spheroids, mice that received (con-
trolFLK-1++hMSC) spheroids also displayed decreased
limb necrosis compared to no treatment group (Figure 6K).
However, these mice still showedmuscle degeneration and
inflammation in the ischemic region (Figures 6I and 6J)
and 18.2% of them eventually lost limb (Figure 6K). No
statistical difference was observed in fibrotic area
between the two groups that received hMSC spheroids
or (controlFLK-1++hMSC) spheroids. In contrast, mice
that received (FLK-1+(+DOX)+hMSC) spheroids were
protected from limb muscle necrotic damage (Figures 6I
and 6J). The majority of the mice that received (FLK-
1+(+DOX)+hMSC) spheroids exhibited limb salvage
(86.4%) with only mild limb necrosis (9.1%). Only 1 of
the 22 mice (4.5%) lost limb (Figure 6K).
Laser Doppler perfusion imaging analysis (Figure 6L)
revealed that blood perfusion in ischemic limbs was sig-
nificantly improved in the group that received (FLK-
1+(+DOX)+hMSC) spheroids compared to the other
groups. Seven days after treatment, the relative ratios of
blood flow (ischemic to normal limb) were 35.6% ± 6.0%
in the (FLK-1+(+DOX)+hMSC) spheroid-recipient group
compared to the other groups (no treatment, 5.3% ±
2.2%; hMSC spheroid recipients, 13.2% ± 1.8%;
controlFLK-1++hMSC spheroid recipients, 14.4% ± 2.8%;
Figure 6L). By day 28, (FLK-1+(+DOX)+hMSC) spheroid-
transplanted group significantly improved the relative
ratio of blood perfusion (72.6% ± 6.8%) compared to the
other groups (no treatment, 3.1% ± 1.7%; hMSC spheroid
recipients, 44.6% ± 7.7%; controlFLK-1++hMSC spheroid
recipients, 47.4% ± 5.1%; Figure 6L). No statistical differ-
ence was observed between the hMSC spheroid and
(controlFLK-1++hMSC) spheroid transplantation group.
Mice that received (FLK-1+(+DOX)+hMSC) spheroids dis-
played significantly enhanced CD31+ microvessel forma-
tion compared to the other groups (Figures 7A and 7C).
SMA-a+ microvessel formation was also significantlyy EGS-Induced FLK-1+-hMSC Spheroid Transplantation
otic cells: CASPASE-3 (red), transplanted EGS-induced FLK-1+ cells:
ar = 50 mm). Arrows point to the apoptotic cells derived from EGS-
ischemic lesion (*p < 0.01, 24 mice/group).
enic paracrine factors from day 3 samples.
1, 24 mice/group).
transplantation (scale bar = 200 mm).
ermined by ELISA (*p < 0.01 compared to the FLK-1+(+DOX)+hMSC
istological ischemic limb sections 28 days after treatments (blue
< 0.01 compared to normal group; 22 mice/group.
blood perfusion (L) of ischemic hindlimbs. Laser Doppler imaging
t the samemagnification. In (L), p < 0.01 compared to no treatment
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Enhanced Hemangioblast Generation from ESCsenhanced by (FLK-1+(+DOX)+hMSC) spheroid transplan-
tation (Figures 7B and 7C). Significant number of EGS-
induced FLK-1+-derived Y+CD31+ (Figures 7A, 7C, and
S7A) or Y+SMA-a+ cells (Figures 7B, 7C, and S7A) were
observed in the vasculature. Although a similar number
of donor-derived (Y+) cells were detected 28 days after
transplantation in mice that received control FLK-1+ or
EGS-induced FLK-1+ cells, very few control FLK-1+-derived
Y+CD31+ or Y+SMA-a+ cells were found in the vasculature
(Figures 7A–7C). Most of the control FLK-1+ or EGS-
induced FLK-1+ progeny cells were found in close prox-
imity to CD31+ or SMA-a+ microvessels. Many more
bromodeoxyuridine (BrdU)-positive microvessels (newly
formed microvessels) were detected in limb tissues trans-
planted with (FLK-1+(+DOX)+hMSC) spheroids compared
to the other groups (Figure 7D). While human VEGF,
bFGF, andHGF proteins were robustly detected (Figure 7D),
human-specific SMA-a or CD31 expression was not
detected (Figure 7C), suggesting that the contribution of
hMSCs to the vascular repair in all conditions are restricted
to paracrine effects.
To determine if therapeutic effect was still observed
with reduced cell number of EGS-induced FLK-1+ cells,
mice (n = 8 each) were injected with 6 3 105 hMSC or
(FLK-1+(+DOX)+hMSC) spheroids (1 3 105 EGS-induced
FLK-1+ cells + 5 3 105 hMSCs) after ischemia induction
and assessed for their recovery. Compared to the group
that received no treatment or hMSC spheroids only, mice
that received reduced number of (FLK-1+(+DOX)+hMSC)
spheroids still dramatically enhanced angiogenesis, blood
flow increase, and limb salvagewith reducedmuscle degen-
eration and tissue fibrosis (Figure S6). We also observed
abundant Y+CD31+ or Y+SMA-a+ cells in nascent vessels
(Figure S6). This indicated that vascular therapeutic effect
could be achieved with as little as 1 3 105 EGS-induced
FLK-1+ cells.
Finally, we confirmed that EGS-induced FLK-1+ cell
outcome was indeed restricted to vessel contribution in
noninjury model. Specifically, we injected ESCs or (FLK-
1+(+DOX)+hMSC) spheroids subcutaneously into mice.
As expected,mice that received ESCs formed distinctive ter-
atomas, which contained multiple tissue types, including
cartilage, glands, neuroepithelium, bone, skin, and vesselsFigure 7. EGS-Induced FLK-1+-Derived Endothelial and Smooth M
(A and B) Merged immunofluorescent staining images of Y-chromoso
28 days after transplantation. Scale bar indicates 100 mm in low mag
(C) Quantification of CD31 or SMAa-positive microvessel density in
(*p < 0.01 and #p < 0.05 compared to the normal group; 22 mice/grou
also accessed with RT-PCR.
(D) Newly formed microvessel density was analyzed by BrdU-positive
lesion. (The asterisk indicates p < 0.01 compared to the normal grou
See also Figures S6 and S7 and Table S2.
Stem C(Figures S7B and S7D). However, mice transplanted with
(FLK-1+(+DOX)+hMSC) spheroids contained only endo-
thelial and smooth muscle cells (Figures S7C and S7D).DISCUSSION
We transiently coexpressed Er71, Gata2, and Scl during
mesoderm formation stage in differentiating ESCs and
greatly augmented hemangioblast generation, while near-
completely blocking cardiac output. Similarly, we could
convert hematopoietic field of the anterior lateral plate
mesoderm into cardiac by inhibiting all three hemangio-
genic factors in zebrafish. This implies that ER71, GATA2,
and SCL form a central core network in hemangioblast
development. Enforced ER71, GATA2, and SCL genetic pro-
gram in ESCs resulted in activation of the BMP-4 and VEGF
receptor 2 signaling pathways and inhibition of the PI3K
and WNT signaling. Remarkably, each factor contributed
uniquely to these signaling pathways, and the collective
sum of these was essential for the final hemangioblast
outcome.
From the characterizations of enforced Er71,Gata2, or Scl
expression in ESCs and the three factor morphants in
zebrafish, we propose that ER71 function is upstream of
GATA2 and SCL and is required at the commitment stage
of hemangioblast generation. GATA2 and SCL maintain
the hemangioblast phenotype by suppressing the cardiac
program. Indeed, ER71 alone could significantly induce
hemangioblasts from ESCs. Moreover, etsrp inhibition
alone was most powerful in blocking hemangiogenic
outcome and converting it into cardiac field in zebrafish.
In developing embryos and differentiating ESCs, Er71
expression is detected prior to Gata2 and Scl expression.
Enforced Er71 expression strongly upregulated Gata2 and
Scl expression within 12 hr. On the other hand, enforced
Gata2 or Scl expression failed to upregulate Er71. Previous
studies suggested that Gata2 and Scl are direct targets of
ER71 (Kataoka et al., 2011). We also observed ER71 occu-
pancy on the Scl promoter region. Recent studies that
only the FLK-1+PDGFRa+ cardiac mesoderm is generated
from Er71-deficient ESCs (Liu et al., 2012), that vascular
endothelial and endocardial progenitors differentiate asuscle Cells Are Abundantly Found within Functional Vessels
me and CD31 (A) or Y and SMAa (B) of ischemic hindlimb tissues
nification and 70 mm high magnification.
the ischemic region and microvessels with Y-chromosome signals
p). Human- or mouse-specific gene expression for microvessels were
microvessels and relative amount of microvessels in the ischemic
p; 22 mice/group).
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et al., 2011), and that cardiac program was readily dere-
pressed in Scl deficient endothelial cells (Van Handel
et al., 2012) support this notion.
We demonstrated that ESC-derived, EGS-induced FLK-1+
hemangioblasts generated functional endothelial and
smooth muscle cells in vivo, as demonstrated by CD31+
as well as SMAa+ vessel structures produced from the
EGS-induced FLK-1+ cells in Matrigel plugs. More impor-
tantly, we were successful in protecting EGS-induced
FLK-1+ cells from apoptosis while preserving their differen-
tiation potential by generating spheroids with hMSCs,
which provided survival signal as well as paracrine angio-
genic factors. Consequently, EGS-induced FLK-1+-derived
endothelial and smooth muscle cells promoted vascular
repair and regeneration in a mouse model of hind-limb
ischemia. Control FLK-1+ cells were also able to dif-
ferentiate into functional endothelial and smooth muscle
cells. However, they were less efficient in their vascular
repair and regeneration potential, probably due to their
heterogeneous nature of both cardiac and hemangiogenic
potential. Our studies are exciting, as there is great interest
in applying stem cell-based therapies for peripheral arterial
disease. Clinical trials, phase I and II, have shown that
endothelial progenitor cells (EPCs), bone marrow-derived
mononuclear cells, MSCs, or the combinations of these
cell types are beneficial for patients with limb ischemia or
acute myocardial infarction (Katritsis et al., 2005; Lasala
et al., 2010, 2012; reviewed in Critser and Yoder, 2010
and Minguell et al., 2013). Moreover, several studies have
reported that pluripotent stem-derived mature endothelial
cells could improve angiogenic repair and regeneration
(Cho et al., 2007; Rufaihah et al., 2011). Currently, how-
ever, limitations still exist in applying either pluripotent
stem-derived endothelial cells, EPCs, or MSCs clinically.
For example, mature endothelial cells have a limited
life span. Direct injection of ESC-derived endothelial
cells into damaged ischemic area in animal models has
met with limited success, due to apoptosis resulting
in limited engraftment. We envision that ESC-derived
FLK-1+ vascular progenitors would be ideal for future
therapeutic applications in peripheral arterial disease. The
current strategy of EGS-induced FLK-1+ cell delivery with
MSCs as vascular tissue spheroids could also be extended
to additional cell types, including EPCs and bone marrow
mononuclear cells.
In summary, we developed a powerful strategy gener-
ating hemangiogenic FLK-1+ progenitors from ESCs. The
unlimited access to hemangioblasts, the ultimate hemato-
poietic and vascular progenitors, warrants further investi-
gations on potential clinical applications requiring
hematopoietic, vascular repair and regeneration. In the
future, however, a strategy of deleting the exogenous genes180 Stem Cell Reports j Vol. 1 j 166–182 j August 6, 2013 j ª2013 The Authafter hemangioblast induction should be considered.
Derivation and future applications of hemangioblasts
from human pluripotent stem cells in peripheral arterial
diseases are warranted.EXPERIMENTAL PROCEDURES
ESC Generation
Er71+/+ and Er71/ ESC lines and inducible ESC lines (iEr71 and
iGata2) were generated as described previously (Lee et al., 2008;
Liu et al., 2012; Lugus et al., 2007). Inducible Scl or Er71-2A-
Gata2-2A-Scl (iEGS) ESCs were generated by targeting the tet-
responsive locus of A2Lox cells (Ismailoglu et al., 2008), with the
construct containing the coding sequence of Scl or Er71, Gata2,
and Scl, which were linked by 2A peptides (de Felipe, 2002). Scl
was fused to a Flag tag at the 30 end. After the correct targeting
event was confirmed by a tet-responsive locus/complementary
DNA vector-specific PCR, inducible Scl or Er71, Gata2, and Scl
expression with 1 mg/ml DOX was verified by RNA and Immuno-
blot analyses.Microarray and Pathway Enrichment Analysis
Global gene expression profiles were analyzed using the GeneChip
Mouse Gene 1.0 ST arrays (Affymetrix). Data were normalized,
and expression values were modeled with Partek Genomics Suite
(Partek). Differentially expressed genes were determined with sig-
nificant p value < 0.05 and false discovery rate < 0.25. Raw data
are available at the Gene Expression Omnibus repository (acces-
sion number GSE45147). Based on the microarray data, pathway
enrichment analysis and interaction networks building were per-
formed using MetaCore Analytical Suite (GeneGo).Mouse Hindlimb Ischemia
Hindlimb ischemia was induced in mice as previously described
(Shim et al., 2012). Four-week-old female athymic mice (20–25 g
body weight; Jackson Laboratory) were anesthetized with xylazine
(10 mg/kg) and ketamine (100 mg/kg). The femoral artery and
its branches were ligated via skin incision using a 6-0 silk suture
(Ethicon), along with the external iliac artery and all upstream
arteries. The femoral artery was then excised from its proximal
origin as a branch of the external iliac artery to the distal point,
whereupon it bifurcates into the saphenous and popliteal arteries.
All animals received humane care (Institutional Animal Care and
Use Committee No. 20110260).Transplantation of FLK-1+(+DOX)+hMSC Spheroids
into Ischemic Mouse Hindlimbs
Mice were randomly divided into five groups (n = 22 from three in-
dependent experiments). Normal mice that did not undergo any
surgery or mice with surgery but without treatment were used as
controls. hMSC, controlFLK-1++hMSC or FLK-1+(+DOX)+hMSC
spheroids (3 3 104 cells/spheroid; 100 spheroids/limb; total 3 3
106 cells/limb; 0.5 3 106 EGS-induced FLK-1+ cells + 2.5 3 106
hMSC cells/limb) were intramuscularly injected into the gracilis
muscle of the medial thigh.ors
Stem Cell Reports
Enhanced Hemangioblast Generation from ESCsLaser Doppler Imaging Analysis
Laser Doppler imaging analysis was performed as described previ-
ously (Shim et al., 2012). A laser Doppler perfusion imager (Moor
Instruments) was used for serial noninvasive physiological evalua-
tion of neovascularization. Mice were monitored by serial scan-
ning of surface blood flow in hindlimbs at days 0, 7, 14, 21, and
28. Digital color-coded images were scanned and analyzed to
quantify a blood flow in ischemic regions from the knee joint to
the toe. Mean values of perfusion were subsequently calculated.
The morphological status of the ischemic limb was monitored
for 4 weeks.
Statistical Analysis
The results of qRT-PCR and flow cytometry analysis were analyzed
by Student’s t test or one-way ANOVA (four group comparisons)
with a Bonferroni multiple comparison posttest (GraphPad soft-
ware). A p value <0.05 was considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, seven figures, and four tables and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
2013.06.005.
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